UY30098A1 - Compuestos de tiazol y metodos de uso - Google Patents

Compuestos de tiazol y metodos de uso

Info

Publication number
UY30098A1
UY30098A1 UY30098A UY30098A UY30098A1 UY 30098 A1 UY30098 A1 UY 30098A1 UY 30098 A UY30098 A UY 30098A UY 30098 A UY30098 A UY 30098A UY 30098 A1 UY30098 A1 UY 30098A1
Authority
UY
Uruguay
Prior art keywords
compounds
tiazol
methods
compositions
formula
Prior art date
Application number
UY30098A
Other languages
English (en)
Spanish (es)
Inventor
Gelld Tadesse
Chester Chenguang Yuan
Guomin Yao
George Erich Wohlhieter
Kurt Edward Weiler
Xianghong Wang
Vellarkad N Viswanadhan
Andrew Tasker
James Thomas Rider
Qingyian Liu
Aiwen Li
Matthew Lee
Xin Huang
Fang-Tsao Hong
Nianhe Han
Christopher H Fotsch
Celia Dominguez
Matthew Paul Boubeau
John Gordon Allen
Qingyi Zeng
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY30098A1 publication Critical patent/UY30098A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY30098A 2006-01-18 2007-01-18 Compuestos de tiazol y metodos de uso UY30098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18

Publications (1)

Publication Number Publication Date
UY30098A1 true UY30098A1 (es) 2007-10-31

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30098A UY30098A1 (es) 2006-01-18 2007-01-18 Compuestos de tiazol y metodos de uso

Country Status (21)

Country Link
US (2) US7514566B2 (OSRAM)
EP (1) EP1981884B1 (OSRAM)
JP (1) JP5199885B2 (OSRAM)
KR (1) KR20080091369A (OSRAM)
CN (1) CN101421265A (OSRAM)
AR (1) AR059064A1 (OSRAM)
AU (1) AU2007207743B2 (OSRAM)
BR (1) BRPI0706621A2 (OSRAM)
CA (1) CA2636077C (OSRAM)
CR (1) CR10211A (OSRAM)
EA (1) EA200801716A1 (OSRAM)
ES (1) ES2389062T3 (OSRAM)
IL (1) IL192751A0 (OSRAM)
MY (1) MY149143A (OSRAM)
NO (1) NO20083572L (OSRAM)
PE (1) PE20071114A1 (OSRAM)
TW (1) TW200738657A (OSRAM)
UA (1) UA91895C2 (OSRAM)
UY (1) UY30098A1 (OSRAM)
WO (1) WO2007084391A2 (OSRAM)
ZA (1) ZA200806386B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004551A (es) * 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
BRPI0706621A2 (pt) * 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
EP2125749A2 (en) * 2007-02-13 2009-12-02 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
WO2009011880A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
CA2693473A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110092423A1 (en) * 2008-06-26 2011-04-21 GlaxoSmithKline, LLC INHIBITORS OF Akt ACTIVITY
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
EA201170349A1 (ru) * 2008-08-18 2011-08-30 Йейл Юниверсити Модуляторы mif
SI3135672T1 (sl) * 2008-10-10 2020-07-31 Vm Discovery, Inc. Sestavki in postopki za zdravljenje motenj, bolečin in drugih bolezni povezanih z uporabo alkohola
US8232273B2 (en) * 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
WO2010083246A1 (en) * 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
HUE033442T2 (en) * 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
US8796298B2 (en) * 2009-10-08 2014-08-05 Glaxosmithkline Llc Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer
PL2485593T3 (pl) * 2009-10-08 2015-06-30 Novartis Ag Kombinacja
BR112012008519A2 (pt) * 2009-10-12 2016-04-05 Glaxosmithkline Llc combinação
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
KR20130038224A (ko) * 2010-03-15 2013-04-17 가부시키가이샤 구라레 티에노피리딘 유도체 및 그 제조 방법, 그리고 그것을 사용한 유기 반도체 디바이스
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 （アリール）ジフルオロ酢酸エステル誘導体及びその製造方法
WO2011130478A1 (en) * 2010-04-16 2011-10-20 Abbott Laboratories Phthalazin-(2h)-one inhibitors of kinases
US20130102605A1 (en) * 2010-04-23 2013-04-25 Peng Liang Inhibitors of akt activity
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
CA2901696C (en) 2013-02-19 2021-04-13 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
MX2015011456A (es) * 2013-03-13 2016-05-31 Boston Biomedical Inc Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
KR102305351B1 (ko) 2013-11-11 2021-09-24 암젠 인크 암의 치료를 위한, mdm2 억제제 및 하나 이상의 추가적 약제학적 활성 제제를 포함하는 조합 요법
TN2017000374A1 (en) * 2015-03-02 2019-01-16 Bristol Myers Squibb Co TGF-β INHIBITORS
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10858355B2 (en) * 2016-03-10 2020-12-08 Astrazeneca Ab Inhibitors of phosphatidylinositol 3-kinase gamma
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3826722A1 (en) 2018-07-24 2021-06-02 F. Hoffmann-La Roche AG Isoquinoline compounds and uses thereof
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms
JP7756070B2 (ja) * 2019-08-02 2025-10-17 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
US12178902B1 (en) 2020-01-12 2024-12-31 University Of Southern California Methods and compositions for fluid drainage by Piezo ion channel activation
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) * 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (OSRAM) 1973-11-08 1977-10-07
US4086239A (en) * 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) * 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) * 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) * 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) * 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) * 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
CA2206315A1 (en) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
CA2332325A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1150565A1 (en) 1999-02-08 2001-11-07 LION bioscience AG Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
EP1205478A4 (en) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd ｐ３８ＭＡＰキナーゼ阻害剤
CA2404384A1 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
US20050080113A1 (en) * 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
MXPA04002914A (es) * 2001-09-28 2005-06-20 Cyclacel Ltd N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
EP1441732A2 (en) * 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
EP1474141A1 (en) 2002-02-13 2004-11-10 Pharmagene Laboratories Ltd 5-ht2b receptor antagonists
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
MXPA04008379A (es) 2002-02-28 2004-11-26 Hoffmann La Roche Derivados de tiazol como antagonistas del receptor de neuropeptido y (npy).
US20040053948A1 (en) * 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
PL376171A1 (en) * 2002-10-09 2005-12-27 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
CA2504320A1 (en) 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
JP2007512230A (ja) 2003-08-20 2007-05-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物
CN1898221A (zh) * 2003-09-06 2007-01-17 沃泰克斯药物股份有限公司 Atp－结合弹夹转运蛋白的调控剂
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
ES2287896T3 (es) 2004-01-12 2007-12-16 Laboratoires Serono Sa Derivados de tiazol y uso de los mismos.
WO2005073202A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
RU2401262C2 (ru) * 2004-01-16 2010-10-10 Санофи-Авентис Производные алкиламинотиазола, их получение и их применение в терапии
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
HRP20080375T3 (hr) 2004-03-23 2008-09-30 Pfizer Products Incorporated Imidazolski spojevi za liječenje neurodegenerativnih poremećaja
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1740609A2 (en) * 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
JP2008502720A (ja) * 2004-05-21 2008-01-31 エムペックス・ファーマシューティカルズ・インコーポレーテッド 細菌の排出ポンプ阻害薬および細菌感染症を治療する方法
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
AU2005272815A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of ATP-utilizing enzymes
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
MX2007004551A (es) * 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
AU2006219231B2 (en) * 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
ES2528451T3 (es) * 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
EP1970377A4 (en) 2005-12-09 2013-02-27 Meiji Seika Kaisha LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE
BRPI0619730A2 (pt) 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 5 membros)-amido
EP1973877A2 (en) 2006-01-18 2008-10-01 Schering Corporation Cannibinoid receptor modulators
AU2007207052B2 (en) 2006-01-18 2012-07-12 F. Hoffmann-La Roche Ag CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors
BRPI0706621A2 (pt) 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
WO2007084391A2 (en) 2007-07-26
ZA200806386B (en) 2009-11-25
PE20071114A1 (es) 2008-01-10
AU2007207743A1 (en) 2007-07-26
KR20080091369A (ko) 2008-10-10
CN101421265A (zh) 2009-04-29
TW200738657A (en) 2007-10-16
WO2007084391A3 (en) 2008-03-20
ES2389062T3 (es) 2012-10-22
US20090270445A1 (en) 2009-10-29
JP5199885B2 (ja) 2013-05-15
NO20083572L (no) 2008-10-17
EA200801716A1 (ru) 2009-04-28
EP1981884B1 (en) 2012-06-13
CA2636077C (en) 2012-01-03
AU2007207743B2 (en) 2010-07-08
JP2009525960A (ja) 2009-07-16
US7514566B2 (en) 2009-04-07
CA2636077A1 (en) 2007-07-26
US20070173506A1 (en) 2007-07-26
IL192751A0 (en) 2009-02-11
BRPI0706621A2 (pt) 2011-04-05
CR10211A (es) 2008-10-03
UA91895C2 (en) 2010-09-10
EP1981884A2 (en) 2008-10-22
AR059064A1 (es) 2008-03-12
MY149143A (en) 2013-07-15
US8084479B2 (en) 2011-12-27

Similar Documents

Publication Publication Date Title
UY30098A1 (es) Compuestos de tiazol y metodos de uso
WO2009011880A3 (en) Heterocyclic modulators of pkb
WO2009011871A3 (en) Thiadiazole modulators of pkb
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
UY30663A1 (es) Dihidropirazolonas sustituidas y su uso
CR9504A (es) Imidazoquinolinas como inhibidores de cinasa de lipido
PA8780101A1 (es) Imidazopiridazina y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
CR11627A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores c-met
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
DK2150530T3 (da) Substituerede sulfonamid-derivater
UY32848A (es) Compuestos heterocíclicos de oxima
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR113211A2 (es) Derivados de bencilfenilciclohexano y métodos de uso
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
ECSP10010532A (es) Tiazolil-dihidro-indazoles
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
ECSP12011748A (es) Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos
UY30550A1 (es) Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170720